S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs

ARS Pharmaceuticals (SPRY) Earnings Date, Estimates & Call Transcripts

$4.68
-0.08 (-1.68%)
(As of 11/27/2023 ET)
Compare
Today's Range
$4.66
▼
$4.81
50-Day Range
$2.92
▼
$6.61
52-Week Range
$2.55
▼
$9.65
Volume
377,466 shs
Average Volume
748,802 shs
Market Capitalization
$449.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Mar. 28Estimated
Actual EPS
(Nov. 9)
-$0.16 Beat By $0.02
Consensus EPS
(Nov. 9)
-$0.18
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SPRY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SPRY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ARS Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.19)($0.13)($0.16)
Q2 20233($0.20)($0.13)($0.17)
Q3 20233($0.20)($0.15)($0.18)
Q4 20234($0.26)($0.17)($0.20)
FY 202312($0.85)($0.58)($0.71)
Q1 20241($0.18)($0.18)($0.18)
Q2 20241($0.18)($0.18)($0.18)
Q3 20241($0.18)($0.18)($0.18)
Q4 20241($0.36)($0.36)($0.36)
FY 20244($0.90)($0.90)($0.90)

SPRY Earnings Date and Information

ARS Pharmaceuticals last issued its quarterly earnings data on November 9th, 2023. The reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. ARS Pharmaceuticals has generated $0.00 earnings per share over the last year. Earnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.64) to ($0.74) per share. ARS Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 28th, 2024 based off prior year's report dates.

ARS Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/28/2024
Estimated)		------- 
11/9/2023Q3 2023($0.18)($0.16)+$0.02($0.16)--
8/10/2023Q2 2023($0.17)($0.18)($0.01)($0.18)-$0.01 million
5/15/2023Q1 2023($0.17)($0.16)+$0.01($0.16)-$0.02 million
11/2/2022Q3 2022-($0.50)($0.50)($0.50)--
8/11/2022Q2 2022($0.62)($0.55)+$0.07($0.55)--
5/12/2022Q1 2022($0.67)($0.70)($0.03)($0.70)--
3/31/2022Q4 2021($0.70)($0.67)+$0.03($0.67)--
11/10/2021Q3 2021($0.72)($0.65)+$0.07($0.65)--
8/12/2021Q2 2021($0.57)($0.70)($0.13)($0.70)--
5/13/2021Q1 2021($0.37)($0.54)($0.17)($0.54)--
3/29/2021Q4 2020($0.61)($1.37)($0.76)($1.37)--












ARS Pharmaceuticals Earnings - Frequently Asked Questions

When is ARS Pharmaceuticals's earnings date?

ARS Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 28th, 2024 based off last year's report dates. Learn more on SPRY's earnings history.

Did ARS Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, ARS Pharmaceuticals (NASDAQ:SPRY) reported ($0.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.18) by $0.02. Learn more on analysts' earnings estimate vs. SPRY's actual earnings.

How much revenue does ARS Pharmaceuticals generate each year?

ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded annual revenue of $1.32 million.

How much profit does ARS Pharmaceuticals generate each year?

ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded net income of -$34.68 million. SPRY has generated $0.00 earnings per share over the last four quarters.

What is ARS Pharmaceuticals's EPS forecast for next year?

ARS Pharmaceuticals's earnings are expected to decrease from ($0.64) per share to ($0.74) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:SPRY) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -